Display options
Cite
Mirza S, Foley RJ. Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Clin Med Insights Circ Respir Pulm Med. 2012;6:41-50doi: 10.4137/CCRPM.S8678.
Mirza, S., & Foley, R. J. (2012). Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 641-50. https://doi.org/10.4137/CCRPM.S8678
Mirza, Shireen, and Foley, Raymond J. "Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension." Clinical medicine insights. Circulatory, respiratory and pulmonary medicine vol. 6 (2012): 41-50. doi: https://doi.org/10.4137/CCRPM.S8678
Mirza S, Foley RJ. Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Clin Med Insights Circ Respir Pulm Med. 2012;6:41-50. doi: 10.4137/CCRPM.S8678. Epub 2012 Jul 24. PMID: 22872790; PMCID: PMC3412595.
Copy Download .nbib Format: NLM
Share it on

Clin Med Insights Circ Respir Pulm Med. 2012;6:41-50. doi: 10.4137/CCRPM.S8678. Epub 2012 Jul 24.

Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension.

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine

Shireen Mirza, Raymond J Foley

Affiliations

  1. Pulmonary and Critical Care Medicine Division, University of Connecticut School of Medicine, Farmington, CT.

PMID: 22872790 PMCID: PMC3412595 DOI: 10.4137/CCRPM.S8678

Abstract

Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients. PAH may be idiopathic in nature or associated with connective tissue disease, chronic liver disease, human immunodeficiency virus, congenital heart disease, and a growing list of other conditions. There are currently nine Food and Drug Administration-approved therapies for specific PAH treatment. Therapeutic targets include prostacyclin replacement, endothelin-1 antagonism, and phosphodiesterase-5 inhibition. This article focuses on the prostanoid treprostinil and explores its role in the management of patients with PAH.

Keywords: New York Heart Association functional class; epoprostenol; hemodynamics; prostanoids; pulmonary arterial hypertension; six minute walk distance; treprostinil

References

  1. Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4 - PubMed
  2. Ann Intern Med. 1994 Sep 15;121(6):409-15 - PubMed
  3. N Engl J Med. 1996 Feb 1;334(5):296-301 - PubMed
  4. Crit Care Nurse. 2007 Apr;27(2):41-2, 44-5, 47-50; quiz 51 - PubMed
  5. Chest. 2007 Jun;131(6):1917-28 - PubMed
  6. Circulation. 2009 Apr 28;119(16):2250-94 - PubMed
  7. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15792-7 - PubMed
  8. Am J Respir Crit Care Med. 2005 Dec 15;172(12):1586-9 - PubMed
  9. J Cardiovasc Pharmacol. 2004 Aug;44(2):209-14 - PubMed
  10. J Clin Pharmacol. 2008 Jan;48(1):19-25 - PubMed
  11. J Heart Lung Transplant. 2010 Feb;29(2):137-49 - PubMed
  12. Chest. 2006 Jun;129(6):1636-43 - PubMed
  13. Eur Heart J. 2009 Oct;30(20):2493-537 - PubMed
  14. MMWR Morb Mortal Wkly Rep. 2007 Mar 2;56(8):170-2 - PubMed
  15. Ann Intern Med. 1991 Sep 1;115(5):343-9 - PubMed
  16. Prostaglandins. 1980 Feb;19(2):319-32 - PubMed
  17. Biochem Biophys Res Commun. 2007 Sep 7;360(4):821-7 - PubMed
  18. Prostaglandins. 1976 Dec;12(6):915-28 - PubMed
  19. J Heart Lung Transplant. 2011 Dec;30(12):1327-33 - PubMed
  20. J Cardiovasc Pharmacol. 2003 Jun;41(6):908-15 - PubMed
  21. N Engl J Med. 1998 Jan 29;338(5):273-7 - PubMed
  22. Eur Respir J. 2006 Dec;28(6):1195-203 - PubMed
  23. Ann Intern Med. 2000 Mar 21;132(6):425-34 - PubMed
  24. J Am Coll Cardiol. 2010 May 4;55(18):1915-22 - PubMed
  25. Circulation. 2000 Dec 19;102(25):3130-6 - PubMed
  26. Chest. 2006 Mar;129(3):683-8 - PubMed

Publication Types